Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
Recruiting · NCT06673628 · Registry updated 2026-06-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients | skin angiosarcoma | Recruiting | Phase 2 | 2026-06-24 | NCT06673628 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| National Cancer Center, Japan | 16 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Faculty of Medicine, University of Miyazaki Hospital | Miyazaki | Japan | 1 |
| Keio University Hospital | Tokyo | Japan | 8 |
| Nagoya City University Hospital | Nagoya | Japan | 1 |
| National Cancer Center Hospital | Tokyo | Japan | 20 |
| National Cancer Center Hospital East | Kashiwa | Japan | 7 |
| University Hospital Kyoto Prefectural University of Medicine | Kyoto | Japan | 3 |